SEARCH

SEARCH BY CITATION

References

  • 1
    National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006.
  • 2
    Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651745.
  • 3
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 2045335.
  • 4
    Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood 2005; 105: 45363.
  • 5
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 41221.
  • 6
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral, direct factor Xa inhibitor (Abstract 905). Blood 2006; 107: 108.
  • 7
    Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct factor Xa inhibitor. J Thromb Haemost 2005; 3: 51421.
  • 8
    Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 276575.
  • 9
    Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study. Lancet 2008; 371: 319.
  • 10
    Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 277686.
  • 11
    Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 1807.
  • 12
    Buller HR, Lensing AWA, Prins MH et al., on behalf of the Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 22427.
  • 13
    He K, He B, Grace JE et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective Factor Xa inhibitor (Abstract 901) Blood 2006; 107: 108.
  • 14
    Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 236875.
  • 15
    Buller H, Deitchman D, Prins M, Segers A, Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 13138.
  • 16
    Bristol-Myers Squibb and Pfizer. Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program (press release), 26 August 2008. http://www.prdomain.com/companies/P/Pfizer/newsreleases/20089361638.htm (accessed December 2008).
  • 17
    Bristol-Myers Squibb and Pfizer. Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program (press release), 26 August 2008. http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1010794&newsId=20080826006372&newsLang=en (accessed December 2008).
  • 18
    Iwatsuki Y, Shigenaga T, Moritani Y et al. Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor (Abstract 911). Blood 2006; 107: 108.
  • 19
    Eriksson BI, Turpie AG, Lassen MR et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 16605.
  • 20
    Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5: 74653.
  • 21
    Zafar MU, Gaztanga J, Velez M et al. A phase-1 study to assess the antithrombotic properties of DU-176b: an orally active direct factor-Xa inhibitor (Abstract 908–161). J Am Coll Cardiol 2006; 47: 288A.
  • 22
    Haas S. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. Drugs 2004; 64: 716.
  • 23
    Nutescu EA, Helgason CM, Briller J, Schwertz DW. New blood thinner offers first potential alternative in 50 years: Ximelagatran. J Cardiovasc Nurs 2004; 19: 37483.
  • 24
    Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 6819.
  • 25
    Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003; 41: 144551.
  • 26
    Olsson S. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 16918.
  • 27
    SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005; 293: 6908.
  • 28
    Wallentin L, Wilcox RG, Weaver WD et al. ESTEEM Investigators Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 78997.
  • 29
    Nisio MD, Middeldorp S, Buller HR. Direct Thrombin Inhibitors. N Engl J Med 2005; 353: 102840.
  • 30
    Agnelli G, Eriksson BI, Cohen AT et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 48897.
  • 31
    AstraZeneca provide update on Ximelagatran. http://www.astrazenecaclinicaltrials.com/article/528850.aspx (accessed December 2008).
  • 32
    Schulman S, Lundstrom T, Walander K, Billing Clason S, Eriksson H. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III Study. Thromb Haemost 2005; 94: 8204.
  • 33
    Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292303.
  • 34
    Eriksson BI, Dahl OE, Ahnfelt L et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 157380.
  • 35
    Geerts WH, Heit JA, Clagett GP et al. Sixth ACCP Consensus Conference on Antithrombotic therapy. Prevention of venous thromboembolism. Chest 2001; 119: 132S75S.
  • 36
    Erisksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 37
    Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 141926.
  • 38
    Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370: 94956.
  • 39
    Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 217885.
  • 40
    The RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 19.
  • 41
    ClinicalTrials.gov Identifier: NCT00808067. http://clinicaltrials.gov/ct2/show/NCT00808067 (accessed December 2008).